Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 1/2021

Open Access 01-01-2021 | Tigecycline | Brief Report

Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents

Authors: Lisa F. Amann, Emilia Ruda Vicente, Mareike Rathke, Astrid Broeker, Maria Riedner, Sebastian G. Wicha

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Purpose

This study aimed to examine the degradation of tigecycline in Mueller Hinton broth (ca-MHB), as knowledge about bacterial susceptibility is key for therapeutic decisions.

Methods

Antioxidative stabilizers were evaluated on tigecycline stability in a quantitative chromatography assay and tigecycline induced kill against Staphylococcus aureus (ATCC29213) was determined in time kill studies.

Results

Ascorbic acid caused rapid degradation of tigecycline and resulted in loss of antibacterial activity. Tigecycline was stabilized in aged broth by 2% pyruvate and bacterial growth, and tigecycline killing was similar to fresh broth without supplementation, but independent of age.

Conclusion

Our results underline the importance of using freshly prepared ca-MHB or the need for stabilizers for tigecycline susceptibility testing while using aged ca-MHB.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pfizer. Tygacil® Full Prescribing Information. 2005 Pfizer. Tygacil® Full Prescribing Information. 2005
6.
go back to reference Wicha SG, Kloft C (2016) Simultaneous determination and stability studies of linezolid, meropenem and vancomycin in bacterial growth medium by high-performance liquid chromatography. J Chromatogr B 1028:242–248CrossRef Wicha SG, Kloft C (2016) Simultaneous determination and stability studies of linezolid, meropenem and vancomycin in bacterial growth medium by high-performance liquid chromatography. J Chromatogr B 1028:242–248CrossRef
Metadata
Title
Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents
Authors
Lisa F. Amann
Emilia Ruda Vicente
Mareike Rathke
Astrid Broeker
Maria Riedner
Sebastian G. Wicha
Publication date
01-01-2021
Publisher
Springer Berlin Heidelberg
Keyword
Tigecycline
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 1/2021
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-020-03970-0

Other articles of this Issue 1/2021

European Journal of Clinical Microbiology & Infectious Diseases 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.